Neuroprotective and Therapeutic Strategies against Parkinson’s Disease: Recent Perspectives
暂无分享,去创建一个
[1] A. Björklund,et al. Characterization of Lewy body pathology in 12‐ and 16‐year‐old intrastriatal mesencephalic grafts surviving in a patient with Parkinson's disease , 2010, Movement disorders : official journal of the Movement Disorder Society.
[2] J. Penney,et al. The functional anatomy of basal ganglia disorders , 1989, Trends in Neurosciences.
[3] R A Crowther,et al. alpha-Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with lewy bodies. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[4] M. Weller,et al. Amantadine and memantine are NMDA receptor antagonists with neuroprotective properties. , 1994, Journal of neural transmission. Supplementum.
[5] B. Giasson,et al. Dityrosine cross-linking promotes formation of stable alpha -synuclein polymers. Implication of nitrative and oxidative stress in the pathogenesis of neurodegenerative synucleinopathies. , 2000, The Journal of biological chemistry.
[6] C. Rebert,et al. Selective nigral toxicity after systemic administration of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyrine (MPTP) in the squirrel monkey , 1984, Brain Research.
[7] D. Maraganore,et al. Immunologic diseases, anti-inflammatory drugs, and Parkinson disease: A case-control study , 2006, Neurology.
[8] A. Lang,et al. The nonmotor symptoms of Parkinson's disease—An overview , 2010, Movement disorders : official journal of the Movement Disorder Society.
[9] F. Horak,et al. Deep brain stimulation for Parkinson disease: an expert consensus and review of key issues. , 2011, Archives of neurology.
[10] R. Barker,et al. Neural grafting in Parkinson's disease Problems and possibilities. , 2010, Progress in brain research.
[11] A. Siderowf,et al. Preclinical diagnosis of parkinson’s disease: Are we there yet? , 2006, Current neurology and neuroscience reports.
[12] D. Guay. Rasagiline (TVP-1012): a new selective monoamine oxidase inhibitor for Parkinson's disease. , 2006, The American journal of geriatric pharmacotherapy.
[13] A. Schapira,et al. TCH346 as a neuroprotective drug in Parkinson's disease: a double-blind, randomised, controlled trial , 2006, The Lancet Neurology.
[14] Alexander Hammers,et al. In vivo imaging of microglial activation with [11C](R)-PK11195 PET in idiopathic Parkinson's disease , 2006, Neurobiology of Disease.
[15] H. Gendelman,et al. Nitrated alpha‐synuclein‐activated microglial profiling for Parkinson’s disease , 2008, Journal of neurochemistry.
[16] W. Jagust,et al. Safety and tolerability of putaminal AADC gene therapy for Parkinson disease , 2009, Neurology.
[17] A. Glavaski-Joksimovic,et al. Mesenchymal stem cells and neuroregeneration in Parkinson's disease , 2013, Experimental Neurology.
[18] Georg Auburger,et al. The ubiquitin pathway in Parkinson's disease , 1998, Nature.
[19] C. Gamba,et al. Neuroprotective effects of human umbilical cord mesenchymal stromal cells in an immunocompetent animal model of Parkinson's disease , 2012, Journal of Neuroimmunology.
[20] M. Selley. Simvastatin prevents 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced striatal dopamine depletion and protein tyrosine nitration in mice , 2005, Brain Research.
[21] F. Binkofski,et al. Nonmotor symptoms in genetic Parkinson disease. , 2010, Archives of neurology.
[22] M. Miller,et al. CEP-1347/KT-7515, an inhibitor of c-jun N-terminal kinase activation, attenuates the 1-methyl-4-phenyl tetrahydropyridine-mediated loss of nigrostriatal dopaminergic neurons In vivo. , 1999, The Journal of pharmacology and experimental therapeutics.
[23] T. Hökfelt,et al. Effect of ergot drugs on central catecholamine neurons: Evidence for a stimulation of central dopamine neurons , 1973, The Journal of pharmacy and pharmacology.
[24] R. Bakay,et al. Delivery of neurturin by AAV2 (CERE‐120)‐mediated gene transfer provides structural and functional neuroprotection and neurorestoration in MPTP‐treated monkeys , 2006, Annals of neurology.
[25] P. Mcgeer,et al. Lewy bodies in Parkinson's disease are recognized by antibodies to complement proteins , 2004, Acta Neuropathologica.
[26] H. Allain,et al. Disease-modifying drugs and Parkinson's disease , 2008, Progress in Neurobiology.
[27] Marios Politis,et al. Serotonergic Neurons Mediate Dyskinesia Side Effects in Parkinson’s Patients with Neural Transplants , 2010, Science Translational Medicine.
[28] Sunhong Kim,et al. Mitochondrial dysfunction in Drosophila PINK1 mutants is complemented by parkin , 2006, Nature.
[29] J. L. Eberling,et al. Results from a phase I safety trial of hAADC gene therapy for Parkinson disease , 2008, Neurology.
[30] M. Beal,et al. NMDA antagonists partially protect against MPTP induced neurotoxicity in mice , 1993, Neuroreport.
[31] P. Brundin,et al. The impact of graft size on the development of dyskinesia following intrastriatal grafting of embryonic dopamine neurons in the rat , 2006, Neurobiology of Disease.
[32] Ross,et al. Relationship between caffeine intake and parkinson disease , 2000, JAMA.
[33] C. Marsden,et al. Alterations in glutathione levels in Parkinson's disease and other neurodegenerative disorders affecting basal ganglia , 1994, Annals of neurology.
[34] Minoru Harada,et al. Tumor necrosis factor-α (TNF-α) increases both in the brain and in the cerebrospinal fluid from parkinsonian patients , 1994, Neuroscience Letters.
[35] The Unified Parkinson's Disease Rating Scale (UPDRS): Status and recommendations , 2003, Movement disorders : official journal of the Movement Disorder Society.
[36] M. Brin,et al. Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. , 1993, The New England journal of medicine.
[37] E. Masliah,et al. Effects of alpha-synuclein immunization in a mouse model of Parkinson's disease. , 2005, Neuron.
[38] Karl Kieburtz,et al. Issues in neuroprotection clinical trials in Parkinson’s disease , 2006, Neurology.
[39] Y. Agid,et al. Stimulation of the subthalamic nucleus in Parkinson’s disease: a 5 year follow up , 2005, Journal of Neurology, Neurosurgery & Psychiatry.
[40] T. van Laar,et al. Chronic stimulation of the subthalamic nucleus increases daily on-time without dyskinesia in advanced Parkinson's disease. , 2006, Parkinsonism & related disorders.
[41] B. E. Staveley,et al. parkin counteracts symptoms in a Drosophila model of Parkinson's disease , 2004, BMC Neuroscience.
[42] M. Tansey,et al. Neuroinflammatory mechanisms in Parkinson's disease: Potential environmental triggers, pathways, and targets for early therapeutic intervention , 2007, Experimental Neurology.
[43] H. Berendse,et al. Idiopathic hyposmia as a preclinical sign of Parkinson's disease , 2004, Annals of neurology.
[44] L. Findley,et al. Olfactory function in essential tremor: A deficit unrelated to disease duration or severity , 2003, Neurology.
[45] M. Gates,et al. Stem cell-derived dopamine neurons for brain repair in Parkinson's disease. , 2010, Regenerative medicine.
[46] H. Federoff,et al. Gene therapeutic strategies for neurodegenerative diseases , 2005 .
[47] F. Horak,et al. Effects of a central cholinesterase inhibitor on reducing falls in Parkinson disease , 2010, Neurology.
[48] O. Hornykiewicz,et al. [The L-3,4-dioxyphenylalanine (DOPA)-effect in Parkinson-akinesia]. , 1961, Wiener klinische Wochenschrift.
[49] E. Melamed,et al. Intrastriatal transplantation of mouse bone marrow-derived stem cells improves motor behavior in a mouse model of Parkinson's disease. , 2007, Journal of neural transmission. Supplementum.
[50] M. Hernán,et al. Nonsteroidal anti-inflammatory drugs and the incidence of Parkinson disease , 2006, Neurology.
[51] A. Hung,et al. Clinical trials for neuroprotection in Parkinson's disease: overcoming angst and futility? , 2007, Current opinion in neurology.
[52] G. Ferrari,et al. The non-immunosuppressive immunophilin ligand GPI-1046 potently stimulates regenerating axon growth from adult mouse dorsal root ganglia cultured in Matrigel , 2002, Neuroscience.
[53] Ninds Net-Pd Investigators. A randomized, double-blind, futility clinical trial of creatine and minocycline in early Parkinson disease. , 2006 .
[54] A. H. V. Schapira,et al. MITOCHONDRIAL COMPLEX I DEFICIENCY IN PARKINSON'S DISEASE , 1989, The Lancet.
[55] M. Merello,et al. Prospective randomized 1-year follow-up comparison of bilateral subthalamotomy versus bilateral subthalamic stimulation and the combination of both in Parkinson's disease patients: a pilot study , 2008, British journal of neurosurgery.
[56] Nicholas W Wood,et al. A common LRRK2 mutation in idiopathic Parkinson's disease , 2005, The Lancet.
[57] B. Ames,et al. Uric acid provides an antioxidant defense in humans against oxidant- and radical-caused aging and cancer: a hypothesis. , 1981, Proceedings of the National Academy of Sciences of the United States of America.
[58] D. Weintraub,et al. Parkinson's disease--Part 3: Neuropsychiatric symptoms. , 2008, The American journal of managed care.
[59] W. Scheper,et al. Activation of the unfolded protein response in Parkinson's disease. , 2007, Biochemical and biophysical research communications.
[60] Elaine Holmes,et al. The application of NMR-based metabonomics in neurological disorders , 2006, NeuroRX.
[61] M. Chesselet,et al. Modelling of Parkinson's disease in mice , 2011, The Lancet Neurology.
[62] J. Obeso,et al. Bilateral deep brain stimulation in Parkinson's disease: a multicentre study with 4 years follow-up. , 2005, Brain : a journal of neurology.
[63] D. Brocks. Anticholinergic drugs used in Parkinson's disease: An overlooked class of drugs from a pharmacokinetic perspective. , 1999, Journal of Pharmacy & Pharmaceutical Sciences.
[64] David Eidelberg,et al. Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson's disease: an open label, phase I trial , 2007, The Lancet.
[65] K. Sethi,et al. A controlled trial of antidepressants in patients with Parkinson’s disease and depression , 2009, Current neurology and neuroscience reports.
[66] A. Schapira. Molecular and clinical pathways to neuroprotection of dopaminergic drugs in Parkinson disease , 2009, Neurology.
[67] Manjit,et al. Neurology , 1912, NeuroImage.
[68] D. Standaert,et al. Targets for neuroprotection in Parkinson's disease. , 2009, Biochimica et biophysica acta.
[69] A. Hofman,et al. Nonsteroidal Anti-Inflammatory Drugs and the Risk of Parkinson Disease , 2007, Neuroepidemiology.
[70] K. Chaudhuri,et al. Non-motor symptoms of Parkinson's disease: dopaminergic pathophysiology and treatment , 2009, The Lancet Neurology.
[71] Changan Jiang,et al. Drosophila pink1 is required for mitochondrial function and interacts genetically with parkin , 2006, Nature.
[72] D. Leibfritz,et al. Free radicals and antioxidants in normal physiological functions and human disease. , 2007, The international journal of biochemistry & cell biology.
[73] C. Marsden,et al. Indices of oxidative stress and mitochondrial function in individuals with incidental Lewy body disease , 1994, Annals of neurology.
[74] A. Carlsson,et al. A fluorimetric method for the determination of dopamine (3-hydroxytyramine). , 1958, Acta physiologica Scandinavica.
[75] Lindy D Wood. Clinical Review and Treatment of Select Adverse Effects of Dopamine Receptor Agonists in Parkinson’s Disease , 2010, Drugs & aging.
[76] H. Braak,et al. Staging of brain pathology related to sporadic Parkinson’s disease , 2003, Neurobiology of Aging.
[77] M. Beal,et al. Creatine and Cyclocreatine Attenuate MPTP Neurotoxicity , 1998, Experimental Neurology.
[78] E. Hirsch,et al. Glial cell participation in the degeneration of dopaminergic neurons in Parkinson's disease. , 1999, Advances in neurology.
[79] Peter Riederer,et al. Transition Metals, Ferritin, Glutathione, and Ascorbic Acid in Parkinsonian Brains , 1989, Journal of neurochemistry.
[80] J. Bloch,et al. Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease. , 2000, Science.
[81] Stanley Fahn,et al. Does levodopa slow or hasten the rate of progression of Parkinson’s disease? , 2005, Journal of Neurology.
[82] H. Reichmann,et al. Olfactory dysfunction as a diagnostic marker for Parkinson’s disease , 2009, Expert review of neurotherapeutics.
[83] K. Paumier,et al. Transplantation of subventricular zone neural precursors induces an endogenous precursor cell response in a rat model of Parkinson's disease , 2009, The Journal of comparative neurology.
[84] R. Barker,et al. The search for biomarkers in Parkinson’s disease: a critical review , 2008, Expert review of neurotherapeutics.
[85] Makoto Hashimoto,et al. Transgenic models of alpha-synuclein pathology: past, present, and future. , 2003, Annals of the New York Academy of Sciences.
[86] D. Perl,et al. Protein Nitration in Parkinson's Disease , 1998, Journal of neuropathology and experimental neurology.
[87] A H V Schapira,et al. Present and future drug treatment for Parkinson’s disease , 2005, Journal of Neurology, Neurosurgery & Psychiatry.
[88] P. Riederer,et al. Interleukin-1β, interleukin-6, epidermal growth factor and transforming growth factor-α are elevated in the brain from parkinsonian patients , 1994, Neuroscience Letters.
[89] N. Hattori,et al. An Unfolded Putative Transmembrane Polypeptide, which Can Lead to Endoplasmic Reticulum Stress, Is a Substrate of Parkin , 2001, Cell.
[90] P. Leigh,et al. Treatment of parkinsonism with bromocriptine. , 1974, Lancet.
[91] Vesna Sossi,et al. A double‐blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease , 2003, Annals of neurology.
[92] Shao-Hua Yang,et al. Pyruvate protects mitochondria from oxidative stress in human neuroblastoma SK-N-SH cells , 2007, Brain Research.
[93] H. Ichinose,et al. Brain-derived growth factor and nerve growth factor concentrations are decreased in the substantia nigra in Parkinson's disease , 1999, Neuroscience Letters.
[94] Howard E. Gendelman,et al. Selective inhibition of NF-κB activation prevents dopaminergic neuronal loss in a mouse model of Parkinson's disease , 2007, Proceedings of the National Academy of Sciences.
[95] G. Celesia,et al. Psychosis and other psychiatric manifestations of levodopa therapy. , 1970, Archives of neurology.
[96] A. J. Valente,et al. Novel Regulation of Parkin Function through c-Abl-Mediated Tyrosine Phosphorylation: Implications for Parkinson's Disease , 2011, The Journal of Neuroscience.
[97] C. Olanow,et al. Transplantation of embryonic dopamine neurons for severe Parkinson's disease. , 2001, The New England journal of medicine.
[98] D. Brooks,et al. Direct brain infusion of glial cell line–derived neurotrophic factor in Parkinson disease , 2003, Nature Medicine.
[99] HOMAS,et al. ASSOCIATION BETWEEN EARLY-ONSET PARKINSON ’ S DISEASE AND MUTATIONS IN THE PARKIN GENE , 2000 .
[100] Joshua J. Neumiller,et al. Clinical review of treatment options for select nonmotor symptoms of Parkinson's disease. , 2010, The American journal of geriatric pharmacotherapy.
[101] Y. Agid,et al. Levodopa: why the controversy? , 2002, The Lancet.
[102] Paola Piccini,et al. Functional brain imaging in the differential diagnosis of Parkinson's disease , 2004, The Lancet Neurology.
[103] R. Godwin-Austen,et al. Comparison of the effects of bromocriptine and levodopa in Parkinson's disease. , 1977, Journal of neurology, neurosurgery, and psychiatry.
[104] Lewis E Kazis,et al. Simvastatin is associated with a reduced incidence of dementia and Parkinson's disease , 2007, BMC medicine.
[105] E. Louis,et al. Olfactory dysfunction in essential tremor: A deficit unrelated to disease duration or severity , 2002 .
[106] Hyon K. Choi,et al. Diet, urate, and Parkinson's disease risk in men. , 2008, American journal of epidemiology.
[107] M. Feany,et al. α-Synuclein phosphorylation controls neurotoxicity and inclusion formation in a Drosophila model of Parkinson disease , 2005, Nature Neuroscience.
[108] K. Jellinger,et al. Reduced and oxidized glutathione in the substantia nigra of patients with Parkinson's disease , 1992, Neuroscience Letters.
[109] A. Björklund,et al. Intracerebral Grafting of Dopamine Neurons , 1987, Annals of the New York Academy of Sciences.
[110] B. Ritz,et al. Statin use and the risk of Parkinson disease , 2008, Neurology.
[111] J. Bolam,et al. Living on the edge with too many mouths to feed: Why dopamine neurons die , 2012, Movement disorders : official journal of the Movement Disorder Society.
[112] D. Jennings,et al. Can we image premotor Parkinson disease? , 2009, Neurology.
[113] P. Löschmann,et al. Protection of substantia nigra from MPP+ neurotoxicity by N-methyl-D-aspartate antagonists , 1991, Nature.
[114] E. Arenas,et al. Differential Effects of Glial Cell Line‐Derived Neurotrophic Factor and Neurturin on Developing and Adult Substantia Nigra Dopaminergic Neurons , 1999, Journal of neurochemistry.
[115] S. Snyder,et al. Neurotrophic actions of nonimmunosuppressive analogues of immunosuppressive drugs FK506, rapamycin and cyclosporin A , 1997, Nature Medicine.
[116] B. Roux,et al. Explaining why Gleevec is a specific and potent inhibitor of Abl kinase , 2013, Proceedings of the National Academy of Sciences.
[117] E. Tolosa,et al. The premotor phase of Parkinson's disease. , 2007, Parkinsonism & related disorders.
[118] A. Smith,et al. Olfactory impairment is more marked in patients with mild dementia with Lewy bodies than those with mild Alzheimer disease , 2009, Journal of Neurology, Neurosurgery, and Psychiatry.
[119] Y. Agid,et al. Apoptosis and autophagy in nigral neurons of patients with Parkinson's disease. , 1997, Histology and histopathology.
[120] Richard W. Murrow,et al. Lower low‐density lipoprotein cholesterol levels are associated with Parkinson's disease , 2007, Movement disorders : official journal of the Movement Disorder Society.
[121] P. James. An Essay on the Shaking Palsy , 1817, The Medico-Chirurgical Journal and Review.
[122] J. Schulz,et al. Gene therapy in Parkinson’s disease , 2004, Cell and Tissue Research.
[123] A. Korczyn. Dopaminergic drugs in development for Parkinson's disease. , 2003, Advances in neurology.
[124] J. Parkinson. An Essay on the Shaking Palsy , 2002 .
[125] C. Hawkes,et al. Olfaction in neurodegenerative disorder. , 2006, Advances in oto-rhino-laryngology.
[126] R. Ridley,et al. Continuous Low-Level Glial Cell Line-Derived Neurotrophic Factor Delivery Using Recombinant Adeno-Associated Viral Vectors Provides Neuroprotection and Induces Behavioral Recovery in a Primate Model of Parkinson's Disease , 2005, The Journal of Neuroscience.
[127] Philippe Hantraye,et al. Dopamine Gene Therapy for Parkinson’s Disease in a Nonhuman Primate Without Associated Dyskinesia , 2009, Science Translational Medicine.
[128] B. de Strooper,et al. Gene therapeutic strategies for neurodegenerative diseases. , 2000, Current opinion in molecular therapeutics.
[129] A. Schapira,et al. Neuroprotection in Parkinson disease: mysteries, myths, and misconceptions. , 2004, JAMA.
[130] E. Hirsch,et al. Neuroinflammation in Parkinson's disease: a target for neuroprotection? , 2009, The Lancet Neurology.
[131] D. Weintraub,et al. Parkinson's disease--Part 2: Treatment of motor symptoms. , 2008, The American journal of managed care.
[132] K. Dujardin,et al. A multicentre study on suicide outcomes following subthalamic stimulation for Parkinson's disease. , 2008, Brain : a journal of neurology.
[133] Jeffrey H. Kordower,et al. The role of α-synuclein in Parkinson's disease: insights from animal models , 2003, Nature Reviews Neuroscience.
[134] M. Yamada,et al. Parkin gene therapy for alpha-synucleinopathy: a rat model of Parkinson's disease. , 2005, Human gene therapy.
[135] Jeffrey H Kordower,et al. The role of alpha-synuclein in Parkinson's disease: insights from animal models. , 2003, Nature reviews. Neuroscience.
[136] A. Antonini,et al. Continuous dopaminergic stimulation achieved by duodenal levodopa infusion , 2008, Neurological Sciences.
[137] A. Benabid. Targeting the caudal intralaminar nuclei for functional neurosurgery of movement disorders , 2009, Brain Research Bulletin.
[138] D. Grosset,et al. The role of radiotracer imaging in Parkinson disease , 2005, Neurology.
[139] R. Bartus,et al. Striatal delivery of neurturin by CERE-120, an AAV2 vector for the treatment of dopaminergic neuron degeneration in Parkinson's disease. , 2007, Molecular therapy : the journal of the American Society of Gene Therapy.
[140] M. Hely,et al. Sydney multicenter study of Parkinson's disease: Non‐L‐dopa–responsive problems dominate at 15 years , 2005, Movement disorders : official journal of the Movement Disorder Society.
[141] K. Chaudhuri,et al. Non-motor symptoms of Parkinson's disease: diagnosis and management , 2006, The Lancet Neurology.
[142] M. Caldwell,et al. Development of stem cell-based therapies for Parkinson's disease , 2016, The International journal of neuroscience.
[143] E. Yoshikawa,et al. Microglial activation and dopamine terminal loss in early Parkinson's disease , 2005, Annals of neurology.
[144] Anatol C. Kreitzer,et al. Striatal mechanisms underlying movement, reinforcement, and punishment. , 2012, Physiology.
[145] C. Fall,et al. Pramipexole Reduces Reactive Oxygen Species Production In Vivo and In Vitro and Inhibits the Mitochondrial Permeability Transition Produced by the Parkinsonian Neurotoxin Methylpyridinium Ion , 1998, Journal of neurochemistry.
[146] A. Schapira,et al. Pramipexole protects against MPTP toxicity in non‐human primates , 2006, Journal of neurochemistry.
[147] H. Bergman,et al. Reversal of experimental parkinsonism by lesions of the subthalamic nucleus. , 1990, Science.
[148] J. Villemure,et al. Effect on mood of subthalamic DBS for Parkinson’s disease A consecutive series of 24 patients , 2002, Neurology.
[149] I. Liste,et al. Progress in Stem Cell Therapy for Major Human Neurological Disorders , 2013, Stem Cell Reviews and Reports.
[150] W. Le,et al. Minocycline inhibits microglial activation and protects nigral cells after 6-hydroxydopamine injection into mouse striatum , 2001, Brain Research.
[151] O. Rascol. “Disease-modification” trials in Parkinson disease: Target populations, endpoints and study design , 2009, Neurology.
[152] M. Poulter,et al. Neuroimmunophilins: A novel drug therapy for the reversal of neurodegenerative disease? , 2004, Neuroscience.
[153] D. Mikulis,et al. A new sensitive imaging biomarker for Parkinson disease? , 2009, Neurology.
[154] C. Mariani,et al. Clinical and neuropsychological follow up at 12 months in patients with complicated Parkinson’s disease treated with subcutaneous apomorphine infusion or deep brain stimulation of the subthalamic nucleus , 2006, Journal of Neurology, Neurosurgery & Psychiatry.
[155] Y. Smith,et al. Glutamate and GABA receptors and transporters in the basal ganglia: What does their subsynaptic localization reveal about their function? , 2006, Neuroscience.
[156] W. Oertel,et al. Combination of 'idiopathic' REM sleep behaviour disorder and olfactory dysfunction as possible indicator for alpha-synucleinopathy demonstrated by dopamine transporter FP-CIT-SPECT. , 2004, Brain : a journal of neurology.
[157] T. Dawson,et al. The role of the ubiquitin-proteasomal pathway in Parkinson's disease and other neurodegenerative disorders , 2001, Trends in Neurosciences.
[158] O. Lindvall,et al. Generation of regionally specified neural progenitors and functional neurons from human embryonic stem cells under defined conditions. , 2012, Cell reports.
[159] L. Raymond,et al. Early synaptic pathophysiology in neurodegeneration: insights from Huntington's disease , 2010, Trends in Neurosciences.
[160] Suk-Ho Lee,et al. Protein-based human iPS cells efficiently generate functional dopamine neurons and can treat a rat model of Parkinson disease. , 2011, The Journal of clinical investigation.
[161] H. Reichmann,et al. Olfactory function in Parkinsonian syndromes , 2002, Journal of Clinical Neuroscience.
[162] H. Uylings,et al. A 100% increase of dopaminergic cells in the olfactory bulb may explain hyposmia in Parkinson's disease , 2004, Movement disorders : official journal of the Movement Disorder Society.
[163] J. Lindon,et al. 'Metabonomics': understanding the metabolic responses of living systems to pathophysiological stimuli via multivariate statistical analysis of biological NMR spectroscopic data. , 1999, Xenobiotica; the fate of foreign compounds in biological systems.
[164] Timothy Lynch,et al. Identification of a novel LRRK2 mutation linked to autosomal dominant parkinsonism: evidence of a common founder across European populations. , 2005, American journal of human genetics.
[165] E. Tolosa. Movement disorders: advances on many fronts , 2007, The Lancet Neurology.
[166] Jeppe Falsig,et al. Progressive Degeneration of Human Mesencephalic Neuron-Derived Cells Triggered by Dopamine-Dependent Oxidative Stress Is Dependent on the Mixed-Lineage Kinase Pathway , 2005, The Journal of Neuroscience.
[167] D. Brooks,et al. A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. , 2000, The New England journal of medicine.
[168] Angelo Antonini,et al. Parkinson's disease: the non-motor issues. , 2011, Parkinsonism & related disorders.
[169] P. Carvey,et al. Attenuation of levodopa-induced toxicity in mesencephalic cultures by pramipexole , 2005, Journal of Neural Transmission.
[170] Y. Kitamura,et al. Protective effects of the antiparkinsonian drugs talipexole and pramipexole against 1-methyl-4-phenylpyridinium-induced apoptotic death in human neuroblastoma SH-SY5Y cells. , 1998, Molecular pharmacology.
[171] O. Lindvall,et al. Prospects of stem cell therapy for replacing dopamine neurons in Parkinson's disease. , 2009, Trends in pharmacological sciences.
[172] B. Hyman,et al. Hsp70 Reduces alpha-Synuclein Aggregation and Toxicity. , 2004, The Journal of biological chemistry.
[173] T. Dawson,et al. Nitric oxide neurotoxicity , 1996, Journal of Chemical Neuroanatomy.
[174] A. Benabid,et al. Long term effects of bilateral subthalamic nucleus stimulation on cognitive function, mood, and behaviour in Parkinson’s disease , 2004, Journal of Neurology, Neurosurgery & Psychiatry.
[175] P. Brundin,et al. Critical issues of clinical human embryonic stem cell therapy for brain repair , 2008, Trends in Neurosciences.
[176] K. Lim,et al. Molecular Events Underlying Parkinson’s Disease – An Interwoven Tapestry , 2013, Front. Neurol..
[177] C D Marsden,et al. Oxidative DNA Damage in the Parkinsonian Brain: An Apparent Selective Increase in 8‐Hydroxyguanine Levels in Substantia Nigra , 1997, Journal of neurochemistry.
[178] T. Iwatsubo,et al. Lentiviral vector delivery of parkin prevents dopaminergic degeneration in an alpha-synuclein rat model of Parkinson's disease. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[179] C. Olanow,et al. Impairment of the ubiquitin‐proteasome system causes dopaminergic cell death and inclusion body formation in ventral mesencephalic cultures , 2002, Journal of neurochemistry.
[180] L. Defebvre,et al. Influence of chronic bilateral stimulation of the subthalamic nucleus on cognitive function in Parkinson's disease , 2001, Journal of Neurology.
[181] Sheng Pan,et al. Using ‘omics’ to define pathogenesis and biomarkers of Parkinson’s disease , 2010, Expert review of neurotherapeutics.
[182] K P Bhatia,et al. The role of DAT-SPECT in movement disorders , 2008, Journal of Neurology, Neurosurgery & Psychiatry.
[183] J L Vitek,et al. Mood changes with deep brain stimulation of STN and GPi: results of a pilot study , 2003, Journal of neurology, neurosurgery, and psychiatry.
[184] Joel S Perlmutter,et al. Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline. , 2002, Archives of neurology.
[185] N. Hattori,et al. [Etiology and pathogenesis of Parkinson's disease: from mitochondrial dysfunctions to familial Parkinson's disease]. , 2004, Rinsho shinkeigaku = Clinical neurology.
[186] Voon Wee Yong,et al. Idiopathic Parkinson's disease, progressive supranuclear palsy and glutathione metabolism in the substantia nigra of patients , 1986, Neuroscience Letters.
[187] J. Jankovic,et al. A double-blind, placebo-controlled and longitudinal study of riluzole in early Parkinson's disease. , 2002, Parkinsonism & related disorders.
[188] Anthony E. Lang,et al. Effect of deprenyl on the progression of disability in early Parkinson's disease. , 1989, The New England journal of medicine.
[189] Han-Joon Kim,et al. Subthalamic Nucleus Deep Brain Stimulation in Parkinson Disease , 2015 .
[190] V. Grill,et al. Effects of Diazoxide on Gene Expression in Rat Pancreatic Islets Are Largely Linked to Elevated Glucose and Potentially Serve to Enhance β-Cell Sensitivity , 2007, Diabetes.
[191] C. Moussa,et al. Nilotinib reverses loss of dopamine neurons and improves motor behavior via autophagic degradation of α-synuclein in Parkinson's disease models. , 2013, Human molecular genetics.
[192] 北田 徹. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism , 1999 .
[193] E. Zamrini,et al. Apoptotic-like changes in Lewy-body-associated disorders and normal aging in substantia nigral neurons. , 1997, The American journal of pathology.
[194] Eugene M. Johnson,et al. MIXED LINEAGE KINASE INHIBITOR CEP- 1347 FAILS TO DELAY DISABILITY IN EARLY PARKINSON DISEASE , 2008, Neurology.
[195] John E. Duda,et al. Olfactory Dysfunction in Parkinson’s Disease , 2007, Neurosignals.
[196] Belinda Wilson,et al. Aggregated α‐synuclein activates microglia: a process leading to disease progression in Parkinson's disease , 2005, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[197] D. Surmeier,et al. Floor plate-derived dopamine neurons from hESCs efficiently engraft in animal models of PD , 2011, Nature.
[198] V. Wheelock,et al. Human Mesenchymal Stem Cells Genetically Engineered to Overexpress Brain-derived Neurotrophic Factor Improve Outcomes in Huntington's Disease Mouse Models , 2016, Molecular therapy : the journal of the American Society of Gene Therapy.
[199] Bonifati,et al. Association between early-onset Parkinson's disease and mutations in the parkin gene. , 2000, The New England journal of medicine.
[200] H. Gendelman,et al. Nitrated α–Synuclein Immunity Accelerates Degeneration of Nigral Dopaminergic Neurons , 2008, PloS one.
[201] S. Paul,et al. Minocycline prevents nigrostriatal dopaminergic neurodegeneration in the MPTP model of Parkinson's disease , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[202] M. Mattson,et al. Dietary folate deficiency and elevated homocysteine levels endanger dopaminergic neurons in models of Parkinson's disease , 2002, Journal of neurochemistry.
[203] R. Hauser,et al. Transplanted dopaminergic neurons develop PD pathologic changes: A second case report , 2008, Movement disorders : official journal of the Movement Disorder Society.
[204] J. Langston,et al. Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. , 1983, Science.
[205] R. de Caterina,et al. Statins and stroke: evidence for cholesterol-independent effects , 2002 .
[206] R. Barker. Developing stem cell therapies for Parkinson's disease: waiting until the time is right. , 2014, Cell stem cell.
[207] A. Johnson,et al. Olfactory function in patients with Parkinson's disease. , 1975, Journal of chronic diseases.
[208] R. Barker,et al. Skin and platelet α-synuclein as peripheral biomarkers of Parkinson's disease , 2005, Neuroscience Letters.
[209] Albert Hofman,et al. Serum cholesterol levels and the risk of Parkinson's disease. , 2006, American journal of epidemiology.
[210] A. Stiggelbout,et al. Systematic evaluation of rating scales for impairment and disability in Parkinson's disease , 2002, Movement disorders : official journal of the Movement Disorder Society.
[211] Mixed lineage kinase inhibitor CEP-1347 fails to delay disability in early Parkinson disease , 2007, Neurology.
[212] A. Crossman. Neural mechanisms in disorders of movement. , 1989, Comparative biochemistry and physiology. A, Comparative physiology.
[213] D. Bozyczko‐Coyne,et al. Inhibition of mixed lineage kinase 3 attenuates MPP+-induced neurotoxicity in SH-SY5Y cells , 2004, Brain Research.
[214] Robert E. Burke,et al. Axon degeneration in Parkinson's disease , 2013, Experimental Neurology.
[215] B. Schmand,et al. Predictors of cognitive and psychosocial outcome after STN DBS in Parkinson's Disease , 2009, Journal of Neurology, Neurosurgery & Psychiatry.
[216] D. Standaert,et al. Rationale for and use of NMDA receptor antagonists in Parkinson's disease. , 2004, Pharmacology & therapeutics.
[217] A. Rezai,et al. AAV2-GAD gene therapy for advanced Parkinson's disease: a double-blind, sham-surgery controlled, randomised trial , 2011, The Lancet Neurology.
[218] A. Siderowf,et al. A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease. , 2004, Archives of neurology.
[219] G. Siegel,et al. Depletion of glial cell line-derived neurotrophic factor in substantia nigra neurons of Parkinson's disease brain , 2001, Journal of Chemical Neuroanatomy.
[220] M. Beal,et al. Coenzyme Q10 attenuates the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) induced loss of striatal dopamine and dopaminergic axons in aged mice , 1998, Brain Research.
[221] Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression. , 2002, JAMA.
[222] David S. Park,et al. Hypersensitivity of DJ-1-deficient mice to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyrindine (MPTP) and oxidative stress. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[223] C. Ustun,et al. Nilotinib: a second-generation tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia. , 2008, Clinical therapeutics.
[224] M. Kohno,et al. Bromocriptine protects mice against 6-hydroxydopamine and scavenges hydroxyl free radicals in vitro , 1994, Brain Research.
[225] H. Adami,et al. Epidemiology and etiology of Parkinson’s disease: a review of the evidence , 2011, European Journal of Epidemiology.
[226] David S. Park,et al. Animal Models of Parkinson's Disease , 2011, Parkinson's disease.
[227] P. Calabresi,et al. Direct and indirect pathways of basal ganglia: a critical reappraisal , 2014, Nature Neuroscience.
[228] C. Adler,et al. Sniffing out Parkinson Disease: Can Olfactory Testing Differentiate Parkinsonian Disorders? , 2007, The neurologist.
[229] R. Bakay,et al. Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2–neurturin) to patients with idiopathic Parkinson's disease: an open-label, phase I trial , 2008, The Lancet Neurology.
[230] W. Slikker,et al. Neuroprotective Efficacy of a New Brain-Penetrating C-Abl Inhibitor in a Murine Parkinson’s Disease Model , 2013, PloS one.
[231] J. Troncoso,et al. Phosphorylation by the c-Abl protein tyrosine kinase inhibits parkin's ubiquitination and protective function , 2010, Proceedings of the National Academy of Sciences.
[232] V. Bolshakov,et al. ES cell-derived renewable and functional midbrain dopaminergic progenitors , 2011, Proceedings of the National Academy of Sciences.
[233] F. Mcdowell,et al. Levodopa, Parkinson's disease, and hypotension. , 1970, Annals of internal medicine.
[234] H. Gendelman,et al. Neuroprotective activities of CD4+CD25+ regulatory T cells in an animal model of Parkinson's disease. , 2007, Journal of leukocyte biology.
[235] P. Riederer,et al. Tumor necrosis factor-alpha (TNF-alpha) increases both in the brain and in the cerebrospinal fluid from parkinsonian patients. , 1994, Neuroscience letters.
[236] B. Shephard,et al. Olfactory function in atypical parkinsonian syndromes , 1995, Acta neurologica Scandinavica.
[237] E. Esposito,et al. Non-steroidal anti-inflammatory drugs in Parkinson's disease , 2007, Experimental Neurology.
[238] Eric Jacobs,et al. Nonsteroidal antiinflammatory drug use and the risk for Parkinson's disease , 2005, Annals of neurology.
[239] Thomas Hummel,et al. Olfactory loss may be a first sign of idiopathic Parkinson's disease , 2007, Movement disorders : official journal of the Movement Disorder Society.
[240] David Blum,et al. Molecular pathways involved in the neurotoxicity of 6-OHDA, dopamine and MPTP: contribution to the apoptotic theory in Parkinson's disease , 2001, Progress in Neurobiology.
[241] M. Stern. The preclinical detection of Parkinson's disease: Ready for prime time? , 2004, Annals of neurology.
[242] P. Liberini,et al. Olfaction in Parkinson’s disease: methods of assessment and clinical relevance , 2000, Journal of Neurology.
[243] S. Minoshima,et al. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism , 1998, Nature.
[244] G. Linazasoro,et al. Dopaminergic agonists in Parkinson's disease. , 2014, Neurologia.
[245] H. Gendelman,et al. Nitrated Alpha-Synuclein and Microglial Neuroregulatory Activities , 2008, Journal of Neuroimmune Pharmacology.
[246] P. Riederer,et al. Interleukin-1 beta, interleukin-6, epidermal growth factor and transforming growth factor-alpha are elevated in the brain from parkinsonian patients. , 1994, Neuroscience letters.
[247] M. Beal,et al. Somatic mitochondrial DNA mutations in single neurons and glia , 2005, Neurobiology of Aging.
[248] C A Ross,et al. Synphilin‐1 is present in Lewy bodies in Parkinson's disease , 2000, Annals of neurology.
[249] R. Crowther,et al. α-Synuclein in filamentous inclusions of Lewy bodies from Parkinson’s disease and dementia with Lewy bodies , 1998 .
[250] Jochen Klucken,et al. Hsp70 Reduces α-Synuclein Aggregation and Toxicity* , 2004, Journal of Biological Chemistry.
[251] T. Dawson,et al. Neuroimmunophilin ligands exert neuroregeneration and neuroprotection in midbrain dopaminergic neurons , 2001, The European journal of neuroscience.
[252] W. Poewe. Parkinson disease: Treatment of the nonmotor symptoms of Parkinson disease , 2010, Nature Reviews Neurology.
[253] Z. Zádori,et al. Mesenchymal Stem Cells of Dental Origin-Their Potential for Anti-inflammatory and Regenerative Actions in Brain and Gut Damage , 2016, Current neuropharmacology.
[254] D. Standaert,et al. Targeted Overexpression of Human &agr;-Synuclein Triggers Microglial Activation and an Adaptive Immune Response in a Mouse Model of Parkinson Disease , 2008, Journal of neuropathology and experimental neurology.
[255] D. Bowers,et al. Cognition and mood in Parkinson's disease in subthalamic nucleus versus globus pallidus interna deep brain stimulation: The COMPARE Trial , 2009, Annals of neurology.
[256] O. Rascol,et al. Neuroprotection in Parkinson's Disease , 1996, The Lancet.
[257] C. Tanner,et al. Levodopa and the progression of Parkinson's disease. , 2004, The New England journal of medicine.
[258] R. Barker,et al. Metabolomic analysis of urine and serum in Parkinson’s disease , 2008, Metabolomics.
[259] A. Björklund,et al. Neural grafting in Parkinson's disease unraveling the mechanisms underlying graft-induced dyskinesia. , 2010, Progress in brain research.
[260] Y. Agid,et al. Long‐term results of a multicenter study on subthalamic and pallidal stimulation in Parkinson's disease , 2010, Movement disorders : official journal of the Movement Disorder Society.
[261] Makoto Hashimoto,et al. Effects of α-Synuclein Immunization in a Mouse Model of Parkinson’s Disease , 2005, Neuron.
[262] R. Constantinescu. Update on the use of pramipexole in the treatment of Parkinson’s disease , 2008, Neuropsychiatric disease and treatment.
[263] N. Ogawa,et al. Immunosuppressive (FK506) and non-immunosuppressive (GPI1046) immunophilin ligands activate neurotrophic factors in the mouse brain , 2003, Brain Research.
[264] Paresh K Doshi,et al. Depression leading to attempted suicide after bilateral subthalamic nucleus stimulation for Parkinson's disease , 2002, Movement disorders : official journal of the Movement Disorder Society.
[265] T. Hummel,et al. 'Sniffin' sticks': olfactory performance assessed by the combined testing of odor identification, odor discrimination and olfactory threshold. , 1997, Chemical senses.
[266] J. Milbrandt,et al. Neurturin Exerts Potent Actions on Survival and Function of Midbrain Dopaminergic Neurons , 1998, The Journal of Neuroscience.
[267] Todd B. Sherer,et al. Chronic systemic pesticide exposure reproduces features of Parkinson's disease , 2000, Nature Neuroscience.
[268] G C Cotzias,et al. Modification of Parkinsonism--chronic treatment with L-dopa. , 1969, The New England journal of medicine.
[269] S. Harik. Changes in the glucose transporter of brain capillaries. , 1992, Canadian journal of physiology and pharmacology.
[270] I. Wilson,et al. Understanding 'Global' Systems Biology: Metabonomics and the Continuum of Metabolism , 2003, Nature Reviews Drug Discovery.
[271] A. Siderowf,et al. Premotor Parkinson's disease: Clinical features and detection strategies , 2009, Movement disorders : official journal of the Movement Disorder Society.
[272] Anthony H V Schapira,et al. Etiology and pathogenesis of Parkinson disease. , 2009, Neurologic clinics.
[273] D. Standaert,et al. Lysosomal enzyme cathepsin D protects against alpha-synuclein aggregation and toxicity , 2008, Molecular Brain.
[274] J. Jankovic,et al. Impact of STN-DBS on life and health satisfaction in patients with Parkinson's disease , 2009, Journal of Neurology, Neurosurgery & Psychiatry.
[275] H. Shill,et al. Abnormal serum concentrations of proteins in Parkinson's disease. , 2009, Biochemical and biophysical research communications.
[276] H. You,et al. Association of Olfactory Bulb Volume and Olfactory Sulcus Depth with Olfactory Function in Patients with Parkinson Disease , 2011, American Journal of Neuroradiology.
[277] A. Carlsson,et al. 3,4-Dihydroxyphenylalanine and 5-Hydroxytryptophan as Reserpine Antagonists , 1957, Nature.
[278] R. Duvoisin,et al. Treatment of parkinsonism with levodopa. , 1969, Archives of neurology.
[279] D. Goldstein,et al. Olfactory dysfunction in pure autonomic failure: Implications for the pathogenesis of Lewy body diseases. , 2009, Parkinsonism & related disorders.
[280] N. Xiong,et al. VEGF-expressing human umbilical cord mesenchymal stem cells, an improved therapy strategy for Parkinson’s disease , 2011, Gene Therapy.
[281] Alexandra Durr,et al. How much phenotypic variation can be attributed to parkin genotype? , 2003, Annals of neurology.
[282] L. Honig. Relationship between caffeine intake and Parkinson disease. , 2000, JAMA.
[283] P. Mcgeer,et al. The Role of Anti-Inflammatory Agents in Parkinson’s Disease , 2007, CNS drugs.
[284] G. Baltuch,et al. Bilateral stimulation of the subthalamic nucleus in patients with Parkinson disease: a study of efficacy and safety. , 2002, Journal of neurosurgery.
[285] J. Langston,et al. The parkinson's complex: Parkinsonism is just the tip of the iceberg , 2006, Annals of neurology.
[286] J. Jankovic,et al. Movement Disorder Society‐sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS‐UPDRS): Process, format, and clinimetric testing plan , 2007, Movement disorders : official journal of the Movement Disorder Society.
[287] Dd Amsterdam. Unilateral pallidotomy versus bilateral subthalamic nucleus stimulation in PD: A comparison of neuropsychological effects , 2005 .
[288] Dong-Kug Choi,et al. Blockade of Microglial Activation Is Neuroprotective in the 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine Mouse Model of Parkinson Disease , 2002, The Journal of Neuroscience.
[289] T. Hirokawa,et al. Alterations of structure and hydrolase activity of parkinsonism-associated human ubiquitin carboxyl-terminal hydrolase L1 variants. , 2003, Biochemical and biophysical research communications.
[290] J. Duda,et al. Olfaction as a biomarker in Parkinson's disease. , 2010, Biomarkers in medicine.
[291] B. Hyman,et al. Nigral and Cortical Lewy Bodies and Dystrophic Nigral Neurites in Parkinson's Disease and Cortical Lewy Body Disease Contain α-synuclein Immunoreactivity , 1998, Journal of neuropathology and experimental neurology.
[292] M. Feany,et al. Alpha-synuclein phosphorylation controls neurotoxicity and inclusion formation in a Drosophila model of Parkinson disease. , 2005, Nature neuroscience.
[293] I. Módy,et al. NMDA receptor-dependent excitotoxicity: the role of intracellular Ca2+ release. , 1995, Trends in pharmacological sciences.
[294] L. Schmued,et al. Neuroprotective effect of the chemical chaperone, trehalose in a chronic MPTP-induced Parkinson's disease mouse model. , 2014, Neurotoxicology.
[295] A. Lang,et al. Serum urate as a predictor of clinical and radiographic progression in Parkinson disease. , 2008, Archives of neurology.
[296] H M M Smeding,et al. Pathological Gambling after bilateral STN stimulation in Parkinson disease , 2008 .
[297] S Blond,et al. Subthalamic nucleus stimulation induces deficits in decoding emotional facial expressions in Parkinson’s disease , 2004, Journal of Neurology, Neurosurgery & Psychiatry.
[298] Mark Stacy,et al. Randomized controlled trial of intraputamenal glial cell line–derived neurotrophic factor infusion in Parkinson disease , 2006, Annals of neurology.
[299] R. Barker,et al. Skin and platelet alpha-synuclein as peripheral biomarkers of Parkinson's disease. , 2005, Neuroscience letters.
[300] Makoto Hashimoto,et al. Transgenic Models of α‐Synuclein Pathology , 2003 .
[301] T. Dawson,et al. Parkin mediates the degradation‐independent ubiquitination of Hsp70 , 2008, Journal of neurochemistry.
[302] C. Ross,et al. Alpha-synuclein phosphorylation enhances eosinophilic cytoplasmic inclusion formation in SH-SY5Y cells. , 2005, The Journal of neuroscience : the official journal of the Society for Neuroscience.
[303] C. Ross,et al. α-Synuclein Phosphorylation Enhances Eosinophilic Cytoplasmic Inclusion Formation in SH-SY5Y Cells , 2005, The Journal of Neuroscience.
[304] P. Perozzo,et al. Chronic Deep Brain Stimulation of the Subthalamic Nucleus for Parkinson’s Disease: Effects on Cognition, Mood, Anxiety and Personality Traits , 2006, European Neurology.
[305] D. Calne,et al. Bromocriptine in Parkinsonism , 1974, British medical journal.
[306] H. Mochizuki,et al. The promises of stem cells: stem cell therapy for movement disorders. , 2014, Parkinsonism & related disorders.
[307] G. Wooten,et al. Maternal inheritance in Parkinson's disease , 1997, Annals of neurology.
[308] Mark P Mattson,et al. Neuronal life-and-death signaling, apoptosis, and neurodegenerative disorders. , 2006, Antioxidants & redox signaling.
[309] P. Hogarth,et al. Pallidal vs subthalamic nucleus deep brain stimulation in Parkinson disease. , 2005, Archives of neurology.
[310] A. Schapira. Mitochondria in the aetiology and pathogenesis of Parkinson's disease , 2008, The Lancet Neurology.
[311] Yoav Ben-Shlomo,et al. The ReSPonD trial - rivastigmine to stabilise gait in Parkinson’s disease a phase II, randomised, double blind, placebo controlled trial to evaluate the effect of rivastigmine on gait in patients with Parkinson’s disease who have fallen , 2013, BMC Neurology.
[312] M. Stern,et al. Deep brain stimulation in Parkinson disease: a metaanalysis of patient outcomes. , 2005, Journal of neurosurgery.
[313] W. Matson,et al. Metabolomic profiling to develop blood biomarkers for Parkinson's disease. , 2008, Brain : a journal of neurology.
[314] M. Merello,et al. Deep Brain Stimulation of the Subthalamic Nucleus for the Treatment of Parkinson's Disease , 2008 .
[315] J. Brotchie,et al. Novel nondopaminergic targets for motor features of Parkinson's disease: Review of recent trials , 2013, Movement disorders : official journal of the Movement Disorder Society.
[316] J. Fantini,et al. Therapeutic Strategies for Neurodegenerative Diseases , 2015 .
[317] H. Reichmann,et al. Biopsies of olfactory epithelium in patients with Parkinson's disease , 2009, Movement disorders : official journal of the Movement Disorder Society.